Your browser doesn't support javascript.
loading
Evaluating the Potential of Polygenic Risk Score to Improve Colorectal Cancer Screening.
Arnau-Collell, Coral; Díez-Villanueva, Anna; Bellosillo, Beatriz; Augé, Josep M; Muñoz, Jenifer; Guinó, Elisabet; Moreira, Leticia; Serradesanferm, Anna; Pozo, Àngels; Torà-Rocamora, Isabel; Bonjoch, Laia; Ibañez-Sanz, Gemma; Obon-Santacana, Mireia; Moratalla-Navarro, Ferran; Sanz-Pamplona, Rebeca; Márquez Márquez, Carmen; Rueda Miret, Rebeca; Pérez Berbegal, Rocio; Piquer Velasco, Gabriel; Hernández Rodríguez, Cristina; Grau, Jaume; Castells, Antoni; Borràs, Josep M; Bessa, Xavier; Moreno, Victor; Castellví-Bel, Sergi.
Affiliation
  • Arnau-Collell C; Gastroenterology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain.
  • Díez-Villanueva A; Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) and University of Barcelona, Barcelona, Spain.
  • Bellosillo B; Pathology Department, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
  • Augé JM; Biochemistry and Molecular Genetics Department, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
  • Muñoz J; Gastroenterology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain.
  • Guinó E; Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) and University of Barcelona, Barcelona, Spain.
  • Moreira L; Gastroenterology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain.
  • Serradesanferm A; Department of Preventive Medicine and Epidemiology, Clinical Institute of Internal Medicine and Dermatology, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona,Barcelona, Spain.
  • Pozo À; Department of Preventive Medicine and Epidemiology, Clinical Institute of Internal Medicine and Dermatology, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona,Barcelona, Spain.
  • Torà-Rocamora I; Department of Preventive Medicine and Epidemiology, Clinical Institute of Internal Medicine and Dermatology, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona,Barcelona, Spain.
  • Bonjoch L; Gastroenterology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain.
  • Ibañez-Sanz G; Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) and University of Barcelona, Barcelona, Spain.
  • Obon-Santacana M; Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) and University of Barcelona, Barcelona, Spain.
  • Moratalla-Navarro F; Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) and University of Barcelona, Barcelona, Spain.
  • Sanz-Pamplona R; Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) and University of Barcelona, Barcelona, Spain.
  • Márquez Márquez C; Gastroenterology Department, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
  • Rueda Miret R; Pathology Department, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
  • Pérez Berbegal R; Gastroenterology Department, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
  • Piquer Velasco G; Pathology Department, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
  • Hernández Rodríguez C; Unitat de Prevenció i Registre del Càncer, Servei d'Epidemiologia i Avaluació, Hospital del Mar, Barcelona, Spain.
  • Grau J; Department of Preventive Medicine and Epidemiology, Clinical Institute of Internal Medicine and Dermatology, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona,Barcelona, Spain.
  • Castells A; Gastroenterology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain.
  • Borràs JM; Department of Clinical Sciences, University of Barcelona and Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Bessa X; Gastroenterology Department, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
  • Moreno V; Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) and University of Barcelona, Barcelona, Spain.
  • Castellví-Bel S; Gastroenterology Department, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Cancer Epidemiol Biomarkers Prev ; 31(7): 1305-1312, 2022 07 01.
Article in En | MEDLINE | ID: mdl-35511747
ABSTRACT

BACKGROUND:

Colorectal cancer has high incidence and associated mortality worldwide. Screening programs are recommended for men and women over 50. Intermediate screens such as fecal immunochemical testing (FIT) select patients for colonoscopy with suboptimal sensitivity. Additional biomarkers could improve the current scenario.

METHODS:

We included 2,893 individuals with a positive FIT test. They were classified as cases when a high-risk lesion for colorectal cancer was detected after colonoscopy, whereas the control group comprised individuals with low-risk or no lesions. 65 colorectal cancer risk genetic variants were genotyped. Polygenic risk score (PRS) and additive models for risk prediction incorporating sex, age, FIT value, and PRS were generated.

RESULTS:

Risk score was higher in cases compared with controls [per allele OR = 1.04; 95% confidence interval (CI), 1.02-1.06; P < 0.0001]. A 2-fold increase in colorectal cancer risk was observed for subjects in the highest decile of risk alleles (≥65), compared with those in the first decile (≤54; OR = 2.22; 95% CI, 1.59-3.12; P < 0.0001). The model combining sex, age, FIT value, and PRS reached the highest accuracy for identifying patients with a high-risk lesion [cross-validated area under the ROC curve (AUROC) 0.64; 95% CI, 0.62-0.66].

CONCLUSIONS:

This is the first investigation analyzing PRS in a two-step colorectal cancer screening program. PRS could improve current colorectal cancer screening, most likely for higher at-risk subgroups. However, its capacity is limited to predict colorectal cancer risk status and should be complemented by additional biomarkers. IMPACT PRS has capacity for risk stratification of colorectal cancer suggesting its potential for optimizing screening strategies alongside with other biomarkers.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Early Detection of Cancer Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Female / Humans / Male Language: En Journal: Cancer Epidemiol Biomarkers Prev Journal subject: BIOQUIMICA / EPIDEMIOLOGIA / NEOPLASIAS Year: 2022 Type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Early Detection of Cancer Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Female / Humans / Male Language: En Journal: Cancer Epidemiol Biomarkers Prev Journal subject: BIOQUIMICA / EPIDEMIOLOGIA / NEOPLASIAS Year: 2022 Type: Article Affiliation country: Spain